Assignee
SUPERNUS PHARMACEUTICALS INC
US·60 granted patents·54 pending applications·240 citations·filing 2003–2025
Top patents by PatentIndex Score
114 records- 0197US11634415B2Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·5 cites·29 claims
- 0296US11964951B2Process of making derivatives of substituted morpholinesSUPERNUS PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·2 cites·23 claims
- 0395US12215097B2Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2024·Granted Feb 4, 2025·1 cites·27 claims
- 0493US7910128B2Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeuticsSUPERNUS PHARMACEUTICALS INC·Filed 2004·Granted Mar 22, 2011·40 cites·27 claims
- 0593US7781448B2Once daily dosage forms of trospiumSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted Aug 24, 2010·6 cites·44 claims
- 0693US7759359B2Method of treating bladder dysfunction with once-a-day trospium salt formulationSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted Jul 20, 2010·6 cites·9 claims
- 0792US11919889B2Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Mar 5, 2024·1 cites·15 claims
- 0892US7410978B2Once daily dosage forms of trospiumSUPERNUS PHARMACEUTICALS INC·Filed 2004·Granted Aug 12, 2008·22 cites·37 claims
- 0991US7611728B2Osmotic delivery of therapeutic compounds by solubility enhancementSUPERNUS PHARMACEUTICALS INC·Filed 2003·Granted Nov 3, 2009·75 cites·17 claims
- 1091US2026008759A1Methods for producing viloxazine salts and novel polymorphs thereofSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1191US2026078098A1Process of making derivatives of substituted morpholinesSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1291US2025367208A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1390US8957206B2Methods of producing molindone and its saltsSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Feb 17, 2015·5 cites·28 claims
- 1490US7781449B2Trospium chloride treatment methodSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted Aug 24, 2010·8 cites·26 claims
- 1590US2025009752A1Method of treatment of attention deficit/hyperactivity disorder (adhd)SUPERNUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1689US9662338B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted May 30, 2017·5 cites·14 claims
- 1788US10265319B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Apr 23, 2019·4 cites·20 claims
- 1888US9358204B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Jun 7, 2016·7 cites·13 claims
- 1988US9119792B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·5 cites·20 claims
- 2087US8709478B2Once daily formulations of tetracyclinesSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Apr 29, 2014·5 cites·37 claims
- 2187US7910131B2Method of treating seizures using modified release formulations of oxcarbazepineSUPERNUS PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·4 cites·24 claims
- 2287US7722898B2Modified-release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2007·Granted May 25, 2010·5 cites·20 claims
- 2387US2023381191A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2486US12569471B2Method of treatment of CNS disordersSUPERNUS PHARMACEUTICALS INC·Filed 2023·Granted Mar 10, 2026·0 cites·4 claims
- 2586US2025122180A1Derivatives of substituted morpholines and uses thereofSUPERNUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2686US2023081113A1Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2785US12121523B2Method of treatment of attention deficit/hyperactivity disorder (ADHD)SUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Oct 22, 2024·0 cites·29 claims
- 2885US9603853B2Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·3 cites·14 claims
- 2984US11077114B2Stabilized formulations of CNS compoundsSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Aug 3, 2021·1 cites·28 claims
- 3084US7749532B2Once daily formulations of tetracyclinesSUPERNUS PHARMACEUTICALS INC·Filed 2004·Granted Jul 6, 2010·10 cites·21 claims
- 3184US2023255892A1Osmotic drug delivery systemSUPERNUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3283US11458143B2Method of treatment of attention deficit/hyperactivity disorder (ADHD)SUPERNUS PHARMACEUTICALS INC·Filed 2022·Granted Oct 4, 2022·0 cites·9 claims
- 3383US8017149B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2008·Granted Sep 13, 2011·2 cites·22 claims
- 3482US10220042B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Mar 5, 2019·1 cites·27 claims
- 3582US9119791B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 1, 2015·2 cites·24 claims
- 3682US2025222004A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3782US2025228859A1Formulations of viloxazineSUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3882US2025228860A1Method of treatment of attention deficit/hyperactivity disorder (adhd)SUPERNUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3981US2023295100A1Process of making derivatives of substituted morpholinesSUPERNUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4080US11896599B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2019·Granted Feb 13, 2024·0 cites·20 claims
- 4180US11166960B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2021·Granted Nov 9, 2021·0 cites·6 claims
- 4279US10201547B2Method of treatment of aggressionSUPERNUS PHARMACEUTICALS INC·Filed 2018·Granted Feb 12, 2019·1 cites·6 claims
- 4379US9855278B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2016·Granted Jan 2, 2018·1 cites·21 claims
- 4479US9144551B2Drug formulations having reduced abuse potentialSUPERNUS PHARMACEUTICALS INC·Filed 2014·Granted Sep 29, 2015·1 cites·15 claims
- 4579US2010069390A1Method of treatment of attention deficit/hyperactivity disorder (ADHD)SUPERNUS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4678US11351120B2Use of higher doses of modified release huperzine formulationsSUPERNUS PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·3 cites·12 claims
- 4778US10058556B2Method of treatment of aggressionSUPERNUS PHARMACEUTICALS INC·Filed 2017·Granted Aug 28, 2018·1 cites·6 claims
- 4878US9370525B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2015·Granted Jun 21, 2016·1 cites·21 claims
- 4978US9351975B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2015·Granted May 31, 2016·1 cites·20 claims
- 5078US8821930B2Modified release preparations containing oxcarbazepine and derivatives thereofSUPERNUS PHARMACEUTICALS INC·Filed 2013·Granted Sep 2, 2014·1 cites·20 claims
Showing the top 50 of 114 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SUPERNUS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →